Shots:The data from P-III (DESTINY-Gastric04) study showed statistically significant and clinically meaningful improvement in OS vs ramucirumab & paclitaxel in 2L HER2+ (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or GEJ adenocarcinoma pts.
The safety profile observed in DESTINY-Gastric04 aligns with Enhertu's established safety record. The company expects to present data…
